Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

TGF-β1/Smad-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TGF-beta/Smad (3) TGF-β Receptor (2) Factor Xa (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (3)

Inhibitors & Agonists

Peptides

Targets Recommended: TGF-β Receptor TGF-beta/Smad

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100444

SIS3 free base 105+ Cited Publications	TGF-beta/Smad	Inflammation/Immunology
SIS3 free base is a potent and selective inhibitor of *Smad3* phosphorylation. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1. SIS3 free base does not affect the phosphorylation of Smad2 .

HY-12274

ML347 5+ Cited Publications LDN 193719	TGF-β Receptor	Cancer
ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC₅₀ values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1 .

HY-P5542

Vicatertide SB-01; Peniel 2000	Factor Xa TGF-beta/Smad	Inflammation/Immunology
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against *TGF-β1* and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the *Smad1/5/8* pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .

HY-P10363

Tiger17	TGF-β Receptor	Others
Tiger17 is an effective wound healing agent. Tiger17 is able to induce the secretion of *TGF-β1* and acts through the Smad signaling pathway, specifically promoting wound healing by increasing the phosphorylation of Smad2 and Smad3 .

HY-176737

*TGF-β1/Smad-IN-1*	TGF-beta/Smad	Inflammation/Immunology
TGF-β1/Smad-IN-1 (compound C9) is a potent *TGF-β1/Smad* inhibitor. TGF-β1/Smad-IN-1 inhibits the expression of fibrosis markers (α-SMA and COL1A1) induced by TGF-β1. TGF-β1/Smad-IN-1 shows antifibrotic effects. TGF-β1/Smad-IN-1 has the potential for the research of hepatic fibrosis .

Cat. No.	Product Name	Target	Research Area

HY-P5542

Vicatertide SB-01; Peniel 2000	Factor Xa TGF-beta/Smad	Inflammation/Immunology
Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against *TGF-β1* and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the *Smad1/5/8* pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases .

HY-P10363

Tiger17	TGF-β Receptor	Others
Tiger17 is an effective wound healing agent. Tiger17 is able to induce the secretion of *TGF-β1* and acts through the Smad signaling pathway, specifically promoting wound healing by increasing the phosphorylation of Smad2 and Smad3 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.